World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
84
Citations
48419
World Ranking
14819
National Ranking
7490

Ravi K. Amaravadi publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ravi K. Amaravadi sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 408 publications — 40th percentile

40% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Ravi K. Amaravadi D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ravi K. Amaravadi sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 84 D-Index — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Ravi K. Amaravadi is affiliated with the University of Pennsylvania in the United States. Their research spans Medicine and Biochemistry, Genetics and Molecular Biology, with a particular focus on Oncology, Immunology, Molecular Biology, Epidemiology, and Infectious Diseases.

Their work concentrates on several interconnected topics within cancer and immunology research. These include Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immunotherapy and Immune Responses, Autophagy in Disease and Therapy, Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways, and Immune Cell Function and Interaction.

Amaravadi has published extensively in several scientific venues. Frequent publication venues for their work include:

  • Journal of Clinical Oncology
  • Nature Communications
  • Cell Reports
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Clinical Cancer Research

The collaboration network of Amaravadi features frequent coauthors who have worked with them on multiple studies. Among these collaborators are Tara C. Mitchell, Lynn M. Schuchter, Giorgos C. Karakousis, Xiaowei Xu, and Alexander C. Huang.

Several notable papers reflect Amaravadi's engagement with autophagy, immunology, and cancer therapies. These recent publications include:

  • "Autophagy in major human diseases" (2021), published in The EMBO Journal
  • "Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms" (2020), published in Immunity
  • "SIRT1 is downregulated by autophagy in senescence and ageing" (2020), published in Nature Cell Biology
  • "Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials" (2021), published in Nature Communications
  • "A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients" (2020), published in Clinical Cancer Research

Best Publications

  • Guidelines for the use and interpretation of assays for monitoring autophagy

    Daniel J. Klionsky;Fabio C. Abdalla;Hagai Abeliovich;Robert T. Abraham

  • Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

    Jeffrey A. Sosman;Kevin B. Kim;Lynn Schuchter;Rene Gonzalez

  • Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

    Christina Twyman-Saint Victor;Andrew J. Rech;Amit Maity;Ramesh Rengan;Ramesh Rengan

  • T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

    Alexander C. Huang;Michael A. Postow;Michael A. Postow;Robert J. Orlowski;Rosemarie Mick

  • TOX transcriptionally and epigenetically programs CD8 + T cell exhaustion

    Omar Khan;Josephine R. Giles;Sierra McDonald;Sasikanth Manne

  • Autophagy in major human diseases

    Daniel J. Klionsky;Giulia Petroni;Ravi K. Amaravadi;Eric H. Baehrecke

  • Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma

    Ravi K. Amaravadi;Duonan Yu;Julian J. Lum;Thi Bui

  • Autophagy in malignant transformation and cancer progression

    Lorenzo Galluzzi;Federico Pietrocola;Federico Pietrocola;José Manuel Bravo-San Pedro;José Manuel Bravo-San Pedro;Ravi K. Amaravadi

  • Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.

    Joseph L. Benci;Bihui Xu;Yu Qiu;Tony J. Wu

  • Systemic Treatment with the Antidiabetic Drug Metformin Selectively Impairs p53-Deficient Tumor Cell Growth

    Monica Buzzai;Russell G. Jones;Ravi K. Amaravadi;Julian J. Lum

  • Principles and current strategies for targeting autophagy for cancer treatment.

    Ravi K. Amaravadi;Jennifer Lippincott-Schwartz;Xiao Ming Yin;William A. Weiss

  • Developmental Relationships of Four Exhausted CD8+ T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms

    Jean-Christophe Beltra;Sasikanth Manne;Mohamed S. Abdel-Hakeem;Makoto Kurachi

  • Targeting Autophagy in Cancer: Recent Advances and Future Directions

    Ravi K. Amaravadi;Alec C. Kimmelman;Jayanta Debnath

  • Recent insights into the function of autophagy in cancer

    Ravi Amaravadi;Alec C. Kimmelman;Eileen White

  • Targeting autophagy in cancer

    Angelique V. Onorati;Matheus Dyczynski;Rani Ojha;Ravi K. Amaravadi

  • The roles of therapy-induced autophagy and necrosis in cancer treatment.

    Ravi K Amaravadi;Craig B Thompson

  • Enhancing CD8 + T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy.

    Ying Zhang;Ying Zhang;Raj Kurupati;Ling Liu;Xiang Yang Zhou

  • A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

    Alexander C. Huang;Robert J. Orlowski;Robert J. Orlowski;Xiaowei Xu;Rosemarie Mick

  • The survival kinases Akt and Pim as potential pharmacological targets.

    Ravi Amaravadi;Craig B. Thompson

  • A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme

    Myrna R. Rosenfeld;Xiaobu Ye;Jeffrey G. Supko;Serena Desideri

Frequent Co-Authors

Lynn M. Schuchter
Lynn M. Schuchter University of Pennsylvania
Xiaowei Xu
Xiaowei Xu University of Pennsylvania
Keith T. Flaherty
Keith T. Flaherty Harvard University
Jeffrey D. Winkler
Jeffrey D. Winkler University of Pennsylvania
Wei Xu
Wei Xu Shenzhen University
E. John Wherry
E. John Wherry University of Pennsylvania
Rosemarie Mick
Rosemarie Mick University of Pennsylvania
Meenhard Herlyn
Meenhard Herlyn The Wistar Institute
Robert H. Vonderheide
Robert H. Vonderheide University of Pennsylvania
Katherine L. Nathanson
Katherine L. Nathanson University of Pennsylvania

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring related online degrees can help broaden your opportunities in healthcare beyond an MD. For those interested in hospital leadership or administration, a healthcare administration degree online offers training in management, finance, and policy, opening doors to high-demand roles in healthcare systems.

Advancing further, a master's in healthcare administration online helps professionals qualify for senior management and executive positions, equipping you with specialized leadership skills.

For clinical advancement, consider exploring the least expensive dnp programs for nurses seeking doctoral-level expertise and a path to advanced practice or leadership roles.

Pharmacy is another promising field—an accelerated 3-year online pharmd can prepare you to become a pharmacist with increased flexibility and speed compared to traditional programs.

These online pathways provide affordability and flexibility for working professionals and recent graduates alike, expanding options to shape your healthcare career.

Best Scientists Citing Ravi K. Amaravadi

Trending Scientists